|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Charles M. Baum M.D., Ph.D.||Founder, Pres, Head of R&D & Director||1,13M||13,06M||1958|
|Mr. Daniel R. Faga||Chief Operating Officer||1,16M||N/D||1980|
|Dr. James G. Christensen Ph.D.||Chief Scientific Officer||820,05k||2,78M||1968|
|Mr. Benjamin J. Hickey||Chief Commercial Officer||798,32k||N/D||1976|
|Mr. David D. Meek||CEO & Director||N/D||N/D||1963|
|Ms. Vickie S. Reed||Sr. VP & Chief Accounting Officer||N/D||N/D||1962|
|Temre Johnson||Director of Investor Relations & Corp. Communications||N/D||N/D||N/D|
|Ms. Reena R. Desai||Gen. Counsel & Corp. Sec.||N/D||N/D||N/D|
|Ms. Kristin Gustafson||Chief HR Officer||N/D||N/D||N/D|
|Dr. Kelly Covello Ph.D.||VP & Head of Medical Affairs||N/D||N/D||N/D|
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 26 settembre 2021 è 8. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 9; diritti degli azionisti: 4; retribuzione: 10.